‘No Decision’ On Sandoz As Novartis Continues To Explore Options
Update To Strategic Review Likely By The End Of The Year
Novartis said it had so far made “no decision” as it continues to consider numerous options for Sandoz, from retaining the business to separation, in order to maximize value for shareholders and capitalize upon the growing autonomy of its generics business.
You may also be interested in...
A management reshuffle at Sandoz has seen head of biopharmaceuticals Pierre Bourdage take on the role of chief operating officer among a number of changes, as parent company Novartis continues its strategic review of the generics and biosimilars unit.
Sandoz has responded to recent rumors that parent company Novartis is favoring a spinoff of the generics and biosimilars business over a sale or retention, insisting that “all options remain open” as a strategic review of the unit continues.
Looking back over the first quarter of 2022, Generics Bulletin executive editor David Wallace picks out highlights from January to March that include a number of major deals in the biosimilars sector, warnings of increasing price pressure on generics, and key strategy updates from companies across the off-patent sector.